Consumer vagus-nerve stimulation lives in three technology lanes that are routinely confused in marketing: transcutaneous auricular tVNS (gammaCore, Truvaga, Nurosym, Pulsetto), transcutaneous cervical tVNS (Pulsetto’s neck position), and vibration-based devices (Apollo Neuro, Sensate) that index parasympathetic activation through somatic stimulation rather than electrical current. Each lane has a different evidence base, regulatory ceiling, and physiological claim. Most consumer purchases are made without understanding which lane the device is in.
What We Compare
Every device in our comparison is evaluated on:
Stimulation modality — electrical (tVNS) vs vibration vs acoustic. Only electrical tVNS has the strongest published electrophysiology pathway to vagal-nerve activation.
FDA clearance status decoded — gammaCore Sapphire holds 510(k) clearance for migraine and cluster headache; most consumer tVNS ships under FDA’s general-wellness policy. “Clinically proven” claims that don’t name the cleared indication are marketing language.
Clinical evidence audit — sham-controlled RCTs only. We flag manufacturer-funded studies and report sample sizes.
HRV (RMSSD) response measurement — a working tVNS device should produce a measurable RMSSD increase over a 5–10 minute session. We use Polar H10 + Kubios as the reference instrument.
Treatment commitment and consumables — gel pads, electrode replacement, app subscription. Pulsetto and Truvaga ship with gel pads that need recurring purchase; Apollo Neuro is gel-free.
Key Findings (2026)
gammaCore Sapphire is the only FDA-cleared cervical vagus-nerve stimulator for at-home consumer use, with 510(k) clearances for migraine, cluster headache, and post-traumatic headache. It’s also the most expensive and prescription-gated. Other consumer brands (Pulsetto, Truvaga, Nurosym) market under general-wellness without disease-treatment claims.
Apollo Neuro and Sensate are not electrical stimulators. Apollo delivers programmed vibration patterns; Sensate uses bone-conducted infrasound. Both have peer-reviewed HRV data but operate through somatic / acoustic pathways, not direct vagal-nerve stimulation. They are valid stress-reduction tools — but call them by their actual mechanism.
Pulsetto has the highest consumer-marketing reach but the thinnest published evidence. 86% user-satisfaction marketing claims are based on internal surveys, not sham-controlled trials. The device may produce HRV changes — we’ll measure independently — but the published evidence is currently weaker than gammaCore’s.
HRV response is the right efficacy proxy for this category. A vagus-stim device that produces no RMSSD change in a 10-minute session is unlikely to deliver downstream benefit. We protocol per-device HRV testing as the empirical floor.
Subscription gating is now common. Pulsetto’s full program library, Truvaga’s app features, and Nurosym’s protocol library are partially subscription-locked. We surface 3-year TCO inclusive of subscription where applicable.
Who Should Read This
Buyers confused about whether Apollo Neuro is a “vagus nerve stimulator” (mechanism is different)
Migraine and cluster-headache patients comparing gammaCore Sapphire to wellness alternatives
Biohackers tracking HRV response to a vagal-toning protocol
Anyone weighing prescription tVNS (gammaCore) against consumer wellness devices